My doctor prescribed a low-dose vaginal estrogen cream, applied twice a week, for atrophic vaginitis. I've heard this dose is so low that it carries no health risk. Do you agree?
ParsonsBoston. Age-adjusted mortality rates for this neoplasm have changed very little during the past four decades in spite of improved lay education and improved methods of surgical, radiological, and medical therapy. The decreased risk of mammary cancer occurrence in the Japanese and the ameliorating influence of pregnancy upon this risk, in proportion to the number of gestations, have suggested to many investigators that genetic and endocrine factors have a role in its pathogenesis.
Active arterial thromboembolic disease e. Acute porphyrias ; diabetes increased risk of heart disease ; factors predisposing to thromboembolism ; history of breast nodules—closely monitor breast status risk of breast cancer ; history of endometrial hyperplasia ; history of fibrocystic disease—closely monitor breast status risk of breast cancer ; hypophyseal tumours ; increased risk of gall-bladder disease ; migraine or migraine-like headaches ; presence of antiphospholipid antibodies increased risk of thrombotic events ; prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer ; risk factors for oestrogen-dependent tumours e. With vaginal use.
Language: English German. On account of the good prognosis for patients with breast cancer, improving or maintaining the quality of life in the aftercare period is becoming more and more important. In particular, the increasing usage of aromatase inhibitors in the past few years has led to an increased incidence of vaginal atrophy with symptoms such as vaginal dryness, petechial bleeding, dyspareunia and recurrent cystitis.
Washington, DC — With 2 million breast cancer survivors now living in the United States, there is growing recognition among health care providers that quality of life issues for these women should be assessed and treated. One particular challenge for providers to understand and address are vaginal symptoms of menopause, whether naturally occurring or treatment-induced. Many therapies that treat estrogen-dependent breast cancer cause vaginal atrophy and increase symptoms of vaginal dryness, bleeding, bacterial infections and painful sex.
For decades, women have used hormone therapy to ease symptoms of menopause, such as hot flashes and sweating. But well-conducted studies have led many doctors to conclude that the risks of MHT often outweigh the benefits. It does not discuss other possible risks of MHT such as heart disease or stroke.
Our belief that breast cancer is preventable is supported by key clinical studies and literature reviews. Lancet Oncol. Interpretation: Because the cumulative incidence among controls did not reach that of the screened group, we believe that many invasive breast cancers detected by repeated mammography screening do not persist to be detected by screening at the end of 6 years, suggesting that the natural course of many of the screen-detected invasive breast cancers is to spontaneously regress.
Estriol provides numerous clinical benefits, commanding the attention of researchers dating as far back as and continues to garner substantial consideration as a valuable and viable therapeutic agent. Some of the most common and effective treatments that employ estriol include: hot flashes, insomnia, skin enhancement, vaginal atrophy and reduced frequency of urinary tract infections. Most recently, estriol has shown the potential to treat individuals with Th1-mediated autoimmune illnesses, including multiple sclerosis and rheumatoid arthritis.
After I testified at a Congressional hearing on natural hormones, a physician who promotes these drugs offered me a free exam and personalized hormone prescription. I thought I felt fine, until I had my hormones balanced…. The biggest marketing push, aimed at menopausal women, has involved so-called bioidentical, or natural, estrogens.
Menopause is characterized by the natural, age-related decrease in endogenous estrogen production in women, often leading to a variety of symptoms such as hot flashes, mood swings and night sweats JohnsonGreendale et al. Conventional United States Food and Drug Administration FDA -approved hormone therapy HT has been used for decades to alleviate these symptoms and is typically administered as estrogen alone to hysterectomized women or an estrogen-progestin combination to women with a uterus JohnsonGreendale et al. While the estrogen component alleviates the symptoms of menopause by compensating for reduced endogenous estrogen production, the progestin constituent counteracts the proliferative effects of estrogens on the uterine epithelium Johnson